Bukwang receives first royalty over Levovir

Published: 2010-06-01 06:58:00
Updated: 2010-06-01 06:58:00
Bukwang said it has received a first royalty of US$31,000 from Eisai Co., for the marketing of Levovir capsule (clevudine) in the Philippines.

Levovir has been prescribed in such country after successful registration from January.

Levovir is the first domestically developed treatment for ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.